key: cord-0730187-erj0fdh8
authors: Wolff, Marcelo J; Acevedo, Mónica L; Núñez, María Antonieta; Lafourcade, Mónica; Gaete-Argel, Aracelly; Soto-Rifo, Ricardo; Valiente-Echeverría, Fernando
title: Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection
date: 2022-02-03
journal: J Travel Med
DOI: 10.1093/jtm/taac010
sha: b0155922b48364c30907f7dc2fa5f2f135817dee
doc_id: 730187
cord_uid: erj0fdh8

We report neutralizing antibody titers (NAbTs) elicited by CoronaVac and BNT162b2 vaccines in healthcare workers with and without prior SARS-CoV-2 infection using both a pseudotype-based assay and a commercial kit. NAbTs were higher for the mRNA vaccine and increased in all previously infected. Good correlation between both assays was found.

We report neutralizing antibody titers (NAbTs) elicited by CoronaVac and BNT162b2 vaccines in healthcare workers with and without prior SARS-CoV-2 infection using both a pseudotypebased assay and a commercial kit. NAbTs were higher for the mRNA vaccine and increased in all previously infected. Good correlation between both assays was found. BNT16b2 vaccine were 18.7-fold or 11.4-fold higher for individuals with vaccine immunity or hybrid immunity, respectively, compared to the respective CoronaVac group (Fig. 1A , Upper panel). We also observed that volunteers with hybrid immunity presented higher neutralizing antibody titers compared with those having vaccine immunity (6.92-fold for CoronaVac and 3.87-fold for BTN162b2; Fig. 1A , Lower panel). Similar results were obtained when anti-spike

we observed a very strong Spearman's correlations between the pseudotyped virus neutralization assay and the commercial kit when analyzed all the samples (R=0.8505).

However, the correlations were moderate to strong (R=0.47, R=0.72, R=0.56, R=0.57) for each group I, II, III and IV, respectively) (Supplementary Figure 1) . In addition, we quantified anti-nucleocapsid antibodies using the Elecsys® Anti-SARS-CoV-2 N kit observing that individuals vaccinated with CoronaVac showed some anti-N antibodies as previously reported 6 , while levels were higher in those previously infected with SARS-CoV-2 (Fig. 1C) . Kruskal-Wallis test after adjustment for the false discovery rate.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Evidence for antibody as a protective correlate for COVID-19 vaccines

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data